Hallucinogens, neuro-immunology and the microbiome — convergent approaches in mental healthcare — mike wang, johns hopkins university.
Mike Wang, is a neuro-psychiatric researcher and adjunct teaching faculty in neuroscience at the Johns Hopkins Krieger School of Arts and Sciences.
Mike is one of the youngest principal investigators at the Johns Hopkins School of Medicine and currently leads a clinical trial examining how hallucinogenic levels of over-the-counter dextromethorphan might serve as the world’s first rapid acting oral antidepressant. (Those interested in the clinical trial for dextromethorphan can.
Mike’s work has been featured in academic journals like the American Journal of Psychiatry, as well as popular outlets like Psychology Today and VICE.
Mike received his graduate training in immunology at the Johns Hopkins Bloomberg School of Public Health studying rare viral encephalitides and neuro-immune determinants of depressive disorders.
Outside of neuro-psychiatry, Mike serves as an educational reform advocate and board member of the educational nonprofit makeLAB.
Comments are closed.